After delivering one of its strongest quarters ever, pharmaceutical major Lupin Ltd. is preparing for the next leg of growth, anchored in complex generics, respiratory therapies, and targeted ...
Alembic Pharmaceuticals is expanding its presence in the United States through a broader portfolio of complex generics, injectables, and an entry into branded drugs following the acquisition of ...
Pacira BioSciences faces significant risk as generic challenges threaten Exparel, its flagship product responsible for 78% of 2024 revenue. PCRX's complex formulation, robust patent estate, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback